Market Research

Liquid Biopsy Market Size, Share & Trends Analysis Report By Biomarker (Exosomes, CTC), By Application (Cancer, Reproductive Health), By Technology, By Sample Type, By Clinical Application, By End-use, By Product, By Region, And Segment Forecasts, 2024 -

Best Price Guarantee Length Publisher Published Date SKU
from $5,950 150 Pages Grand View Research December, 2023 GV18531884
Best Price Guarantee
Price from $5,950
Length 150 Pages
Publisher Grand View Research
Published Date December, 2023
SKU GV18531884

Liquid Biopsy Market Size, Share & Trends Analysis Report By Biomarker (Exosomes, CTC), By Application (Cancer, Reproductive Health), By Technology, By Sample Type, By Clinical Application, By End-use, By Product, By Region, And Segment Forecasts, 2024 - 2030


Liquid Biopsy Market Growth & Trends

The global Liquid Biopsy Market size was valued at USD 22.88 billion in 2030 and is expected to expand at a compound annual growth rate (CAGR) of 9.7% from 2023 to 2030. The increasing prevalence of cancer and the growing geriatric population are major drivers expected to fuel market growth. Furthermore, the use of technologically advanced devices for early detection of diseases is one of the key factors driving the market. In addition, the increasing preference for noninvasive treatment procedures will offer lucrative opportunities in the forecast period.

In recent years, cases of cancer have been rising tremendously and the trend is projected to remain the same in the foreseeable future. A significant shift in lifestyle has exposed the global population to this disorder and has resulted in oncogenic factors. For instance, as per the American Cancer Society, in 2022, the number of new cancer cases is expected to reach 1.9 million, leading to 609,360 deaths. Companies are focusing on expanding their business operations in the clinical liquid biopsy space.

For instance, in December 2021, Helio Health and Fulgent Genetics announced the launch of the former’s HelioLiver, a new liquid biopsy test for early liver cancer detection. This liquid biopsy test combines serum protein markers and cell-free DNA methylation patterns. Additionally, new research studies are aiding the development of novel liquid biopsy techniques. For instance, in July 2022, the University of Central Florida announced the development of a novel liquid biopsy technique that facilitates early detection using biomarker identification for lung and breast cancer, making the monitoring of conditions easier.

The enhanced interest of players in liquid biopsy and the increasing rate of approval of new products are further accelerating market growth. Moreover, in the past several years, studies have shown a positive outcome of liquid biopsy platforms. Governments and various regulatory bodies have also shown interest in the area by promoting multiple breakthrough devices for the rapid development of this technology. With the high adoption of the technology by various companies, along with the support of government funding and initiatives, the market is expected to grow in the coming years.

Liquid Biopsy Market Report Highlights
  • The ctDNA segment is projected to hold the largest share in the market owing to its wide use as a biomarker in the detection of cancer using liquid biopsy
  • The multi-gene-parallel analysis (NGS) technology segment is expected to grow lucratively due to increasing research and development, increasing cancer cases, advancements in technology, and strategic activities by leading companies
  • North America dominated the global market in 2022, owing to the increasing demand for new technologies, a large pool of key players, the presence of several clinical laboratories, and advanced healthcare infrastructure in the region
  • Asia Pacific is expected to grow considerably in the future, owing to the rising prevalence of target conditions in the region and the presence of key players
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List Of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Increasing prevalence of cancer
3.4.2. Growing geriatric population
3.4.3. Technological advancements
3.4.4. Increasing preference for noninvasive treatment
3.5. Market Restraint Analysis
3.5.1. Patent expiry of blockbuster drugs prescribed
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. Liquid Biopsy Market: Type Movement Analysis
4.2. Blood Sample
4.2.1. Blood Sample Market, 2018 - 2030 (USD Million)
4.3. Others
4.3.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Biomarker Business Analysis
5.1. Liquid Biopsy Market: Biomarker Movement Analysis
5.2. Circulating Tumor Cells (CTCs)
5.2.1. Circulating Tumor Cells (CTCs) Market, 2018 - 2030 (USD Million)
5.3. Circulating Tumor DNA (catena)
5.3.1. Circulating Nucleic Acids Market, 2018 - 2030 (USD Million)
5.4. Exosomes/Microvesicles
5.4.1. Exosomes/Microvesicles Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Technology Business Analysis
6.1. Liquid Biopsy Market: Technology Movement Analysis
6.2. Multi-gene-parallel Analysis (NGS)
6.2.1. Multi-gene-parallel Analysis (NGS) Market, 2018 - 2030 (USD Million)
6.3. Single Gene Analysis (PCR Microarrays)
6.3.1. Single Gene Analysis (PCR Microarrays) Market, 2018 - 2030 (USD Million)
Chapter 7. Application Business Analysis
7.1. Liquid Biopsy Market: Application Movement Analysis
7.2. Cancer
7.2.1. Cancer Market, 2018 - 2030 (USD Million)
7.2.1.1. Lung Cancer
7.2.1.2. Lung Cancer Market, 2018 - 2030 (USD Million)
7.2.1.3. Prostate Cancer
7.2.1.4. Prostate Cancer Market, 2018 - 2030 (USD Million)
7.2.1.5. Breast Cancer
7.2.1.6. Breast Cancer Market, 2018 - 2030 (USD Million)
7.2.1.7. Colorectal Cancer
7.2.1.8. Colorectal Cancer Market, 2018 - 2030 (USD Million)
7.2.1.9. Leukemia
7.2.1.10. Leukemia Market, 2018 - 2030 (USD Million)
7.2.1.11. Gastrointestinal Cancer
7.2.1.12. Gastrointestinal Cancer Market, 2018 - 2030 (USD Million)
7.2.1.13. Others
7.2.1.14. Others Market, 2018 - 2030 (USD Million)
7.3. Reproductive Health
7.3.1. Reproductive Health Market, 2018 - 2030 (USD Million)
7.4. Others
7.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 8. End-Use Business Analysis
8.1. Liquid Biopsy Market: End-Use Movement Analysis
8.2. Hospitals and Laboratories
8.2.1. Hospitals and Laboratories Market, 2018 - 2030 (USD Million)
8.3. Specialty Clinics
8.3.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
8.4. Academic and Research Centers
8.4.1. Academic and Research Centers Market, 2018 - 2030 (USD Million)
8.5. Others
8.5.1. Others Liquid Biopsy Market, 2018 - 2030 (USD Million)
Chapter 9. Clinical Application Business Analysis
9.1. Liquid Biopsy Market: Clinical Application Movement Analysis
9.2. Therapy Selection
9.2.1. Therapy Selection Market, 2018 - 2030 (USD Million)
9.3. Treatment Monitoring
9.3.1. Treatment Monitoring Market, 2018 - 2030 (USD Million)
9.4. Early Cancer Screening
9.4.1. Early Cancer Screening Market, 2018 - 2030 (USD Million)
9.5. Recurrence Monitoring
9.5.1. Recurrence Monitoring Market, 2018 - 2030 (USD Million)
9.6. Others
9.6.1. Others Liquid Biopsy Market, 2018 - 2030 (USD Million)
Chapter 10. Product Business Analysis
10.1. Liquid Biopsy Market: Product Movement Analysis
10.2. Instruments
10.2.1. Instruments Market, 2018 - 2030 (USD Million)
10.3. Consumables Kits and Reagents
10.3.1. Consumables Kits and Reagents Market, 2018 - 2030 (USD Million)
10.4. Software and Services
10.4.1. Software and Services Market, 2018 - 2030 (USD Million)
Chapter 11. Regional Business Analysis
11.1. Liquid Biopsy Market Share By Region, 2023 & 2030
11.2. North America
11.2.1. North America Liquid biopsy market, 2018 - 2030 (USD Million)
11.2.2. U.S.
11.2.2.1. Key Country Dynamics
11.2.2.2. Target Disease Prevalence
11.2.2.3. Competitive Scenario
11.2.2.4. Regulatory Framework
11.2.2.5. Reimbursement Scenario
11.2.2.6. U.S. Liquid biopsy market, 2018 - 2030 (USD Million)
11.2.3. Canada
11.2.3.1. Key Country Dynamics
11.2.3.2. Target Disease Prevalence
11.2.3.3. Competitive Scenario
11.2.3.4. Regulatory Framework
11.2.3.5. Reimbursement Scenario
11.2.3.6. Canada Liquid biopsy market, 2018 - 2030 (USD Million)
11.3. Europe
11.3.1. Europe Liquid biopsy market, 2018 - 2030 (USD Million)
11.3.2. Germany
11.3.2.1. Key Country Dynamics
11.3.2.2. Target Disease Prevalence
11.3.2.3. Competitive Scenario
11.3.2.4. Regulatory Framework
11.3.2.5. Reimbursement Scenario
11.3.2.6. Germany Liquid biopsy market, 2018 - 2030 (USD Million)
11.3.3. UK
11.3.3.1. Key Country Dynamics
11.3.3.2. Target Disease Prevalence
11.3.3.3. Competitive Scenario
11.3.3.4. Regulatory Framework
11.3.3.5. Reimbursement Scenario
11.3.3.6. UK Liquid biopsy market, 2018 - 2030 (USD Million)
11.3.4. France
11.3.4.1. Key Country Dynamics
11.3.4.2. Target Disease Prevalence
11.3.4.3. Competitive Scenario
11.3.4.4. Regulatory Framework
11.3.4.5. Reimbursement Scenario
11.3.4.6. France Liquid biopsy market, 2018 - 2030 (USD Million)
11.3.5. Italy
11.3.5.1. Key Country Dynamics
11.3.5.2. Target Disease Prevalence
11.3.5.3. Competitive Scenario
11.3.5.4. Regulatory Framework
11.3.5.5. Reimbursement Scenario
11.3.5.6. Italy Liquid biopsy market, 2018 - 2030 (USD Million)
11.3.6. Spain
11.3.6.1. Key Country Dynamics
11.3.6.2. Target Disease Prevalence
11.3.6.3. Competitive Scenario
11.3.6.4. Regulatory Framework
11.3.6.5. Reimbursement Scenario
11.3.6.6. Spain Liquid biopsy market, 2018 - 2030 (USD Million)
11.3.7. Denmark
11.3.7.1. Key Country Dynamics
11.3.7.2. Target Disease Prevalence
11.3.7.3. Competitive Scenario
11.3.7.4. Regulatory Framework
11.3.7.5. Reimbursement Scenario
11.3.7.6. Denmark Liquid biopsy market, 2018 - 2030 (USD Million)
11.3.8. Sweden
11.3.8.1. Key Country Dynamics
11.3.8.2. Target Disease Prevalence
11.3.8.3. Competitive Scenario
11.3.8.4. Regulatory Framework
11.3.8.5. Reimbursement Scenario
11.3.8.6. Sweden Liquid biopsy market, 2018 - 2030 (USD Million)
11.3.9. Norway
11.3.9.1. Key Country Dynamics
11.3.9.2. Target Disease Prevalence
11.3.9.3. Competitive Scenario
11.3.9.4. Regulatory Framework
11.3.9.5. Reimbursement Scenario
11.3.9.6. Norway Liquid biopsy market, 2018 - 2030 (USD Million)
11.4. Asia Pacific
11.4.1. Asia Pacific Liquid biopsy market, 2018 - 2030 (USD Million)
11.4.2. Japan
11.4.2.1. Key Country Dynamics
11.4.2.2. Target Disease Prevalence
11.4.2.3. Competitive Scenario
11.4.2.4. Regulatory Framework
11.4.2.5. Reimbursement Scenario
11.4.2.6. Japan Liquid biopsy market, 2018 - 2030 (USD Million)
11.4.3. China
11.4.3.1. Key Country Dynamics
11.4.3.2. Target Disease Prevalence
11.4.3.3. Competitive Scenario
11.4.3.4. Regulatory Framework
11.4.3.5. Reimbursement Scenario
11.4.3.6. China Liquid biopsy market, 2018 - 2030 (USD Million)
11.4.4. India
11.4.4.1. Key Country Dynamics
11.4.4.2. Target Disease Prevalence
11.4.4.3. Competitive Scenario
11.4.4.4. Regulatory Framework
11.4.4.5. Reimbursement Scenario
11.4.4.6. India Liquid biopsy market, 2018 - 2030 (USD Million)
11.4.5. South Korea
11.4.5.1. Key Country Dynamics
11.4.5.2. Target Disease Prevalence
11.4.5.3. Competitive Scenario
11.4.5.4. Regulatory Framework
11.4.5.5. Reimbursement Scenario
11.4.5.6. South Korea Liquid biopsy market, 2018 - 2030 (USD Million)
11.4.6. Australia
11.4.6.1. Key Country Dynamics
11.4.6.2. Target Disease Prevalence
11.4.6.3. Competitive Scenario
11.4.6.4. Regulatory Framework
11.4.6.5. Reimbursement Scenario
11.4.6.6. Australia Liquid biopsy market, 2018 - 2030 (USD Million)
11.4.7. Thailand
11.4.7.1. Key Country Dynamics
11.4.7.2. Target Disease Prevalence
11.4.7.3. Competitive Scenario
11.4.7.4. Regulatory Framework
11.4.7.5. Reimbursement Scenario
11.4.7.6. Thailand Liquid biopsy market, 2018 - 2030 (USD Million)
11.5. Latin America
11.5.1. Latin America Liquid biopsy market, 2018 - 2030 (USD Million)
11.5.2. Brazil
11.5.2.1. Key Country Dynamics
11.5.2.2. Target Disease Prevalence
11.5.2.3. Competitive Scenario
11.5.2.4. Regulatory Framework
11.5.2.5. Reimbursement Scenario
11.5.2.6. Brazil Liquid biopsy market, 2018 - 2030 (USD Million)
11.5.3. Mexico
11.5.3.1. Key Country Dynamics
11.5.3.2. Target Disease Prevalence
11.5.3.3. Competitive Scenario
11.5.3.4. Regulatory Framework
11.5.3.5. Reimbursement Scenario
11.5.3.6. Mexico Liquid biopsy market, 2018 - 2030 (USD Million)
11.5.4. Argentina
11.5.4.1. Key Country Dynamics
11.5.4.2. Target Disease Prevalence
11.5.4.3. Competitive Scenario
11.5.4.4. Regulatory Framework
11.5.4.5. Reimbursement Scenario
11.5.4.6. Argentina Liquid biopsy market, 2018 - 2030 (USD Million)
11.6. MEA
11.6.1. MEA Liquid biopsy market, 2018 - 2030 (USD Million)
11.6.2. South Africa
11.6.2.1. Key Country Dynamics
11.6.2.2. Target Disease Prevalence
11.6.2.3. Competitive Scenario
11.6.2.4. Regulatory Framework
11.6.2.5. Reimbursement Scenario
11.6.2.6. South Africa Liquid biopsy market, 2018 - 2030 (USD Million)
11.6.3. Saudi Arabia
11.6.3.1. Key Country Dynamics
11.6.3.2. Target Disease Prevalence
11.6.3.3. Competitive Scenario
11.6.3.4. Regulatory Framework
11.6.3.5. Reimbursement Scenario
11.6.3.6. Saudi Arabia Liquid biopsy market, 2018 - 2030 (USD Million)
11.6.4. UAE
11.6.4.1. Key Country Dynamics
11.6.4.2. Target Disease Prevalence
11.6.4.3. Competitive Scenario
11.6.4.4. Regulatory Framework
11.6.4.5. Reimbursement Scenario
11.6.4.6. UAE Liquid biopsy market, 2018 - 2030 (USD Million)
11.6.5. Kuwait
11.6.5.1. Key Country Dynamics
11.6.5.2. Target Disease Prevalence
11.6.5.3. Competitive Scenario
11.6.5.4. Regulatory Framework
11.6.5.5. Reimbursement Scenario
11.6.5.6. Kuwait Liquid biopsy market, 2018 - 2030 (USD Million)
Chapter 12. Competitive Landscape
12.1. Participant’s overview
12.2. Financial performance
12.3. Participant categorization
12.3.1. Market Leaders
12.3.2. Liquid Biopsy Market Share Analysis, 2023
12.3.3. Company Profiles
12.3.3.1. ANGLE plc
12.3.3.1.1. Company Overview
12.3.3.1.2. Financial Performance
12.3.3.1.3. Product Benchmarking
12.3.3.1.4. Strategic Initiatives
12.3.3.2. Oncimmune Holdings PLC
12.3.3.2.1. Company Overview
12.3.3.2.2. Financial Performance
12.3.3.2.3. Product Benchmarking
12.3.3.2.4. Strategic Initiatives
12.3.3.3. Guardant Health
12.3.3.3.1. Company Overview
12.3.3.3.2. Financial Performance
12.3.3.3.3. Product Benchmarking
12.3.3.3.4. Strategic Initiatives
12.3.3.4. Myriad Genetics, Inc.
12.3.3.4.1. Company Overview
12.3.3.4.2. Financial Performance
12.3.3.4.3. Product Benchmarking
12.3.3.4.4. Strategic Initiatives
12.3.3.5. Biocept, Inc.
12.3.3.5.1. Company Overview
12.3.3.5.2. Financial Performance
12.3.3.5.3. Product Benchmarking
12.3.3.5.4. Strategic Initiatives
12.3.3.6. Lucence Health Inc.
12.3.3.6.1. Company Overview
12.3.3.6.2. Financial Performance
12.3.3.6.3. Product Benchmarking
12.3.3.6.4. Strategic Initiatives
12.3.3.7. Freenome Holdings, Inc.
12.3.3.7.1. Company Overview
12.3.3.7.2. Financial Performance
12.3.3.7.3. Product Benchmarking
12.3.3.7.4. Strategic Initiatives
12.3.3.8. F. Hoffmann-La Roche Ltd.
12.3.3.8.1. Company Overview
12.3.3.8.2. Financial Performance
12.3.3.8.3. Product Benchmarking
12.3.3.8.4. Strategic Initiatives
12.3.3.9. QIAGEN
12.3.3.9.1. Company Overview
12.3.3.9.2. Financial Performance
12.3.3.9.3. Product Benchmarking
12.3.3.9.4. Strategic Initiatives
12.3.3.10. Illumina, Inc.
12.3.3.10.1. Company Overview
12.3.3.10.2. Financial Performance
12.3.3.10.3. Product Benchmarking
12.3.3.10.4. Strategic Initiatives
12.3.3.11. Thermo Fisher Scientific, Inc.
12.3.3.11.1. Company Overview
12.3.3.11.2. Financial Performance
12.3.3.11.3. Product Benchmarking
12.3.3.11.4. Strategic Initiatives
12.3.3.12. Epigenomics AG
12.3.3.12.1. Company Overview
12.3.3.12.2. Financial Performance
12.3.3.12.3. Product Benchmarking
12.3.3.12.4. Strategic Initiatives
12.3.4. Strategy Mapping
12.3.4.1. Expansion
12.3.4.2. Acquisition
12.3.4.3. Collaborations
12.3.4.4. Disease Type/Drug Class Launch
12.3.4.5. Partnerships
12.3.4.6. Others

$5,950
$6,950
$8,950

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings